Kexing Biopharm Partners with BioDlink to Embark on Latin American Markets

Article source：Kexing BiopharmOct 23,2025View： 3046

Recently, the first batch of orders for Kexing Biopharm (stock code: 688136.SH)'s bevacizumab biosimilar was successfully shipped to Colombia — licensed-in by BioDlink. This represents the product's first overseas commercialization shipment following marketing approval.

Bevacizumab is a commonly used drug in the oncology field, indicated worldwide for the treatment of various cancers. Having just received approval from Colombia's drug regulatory authority (INVIMA) not long ago, the rapid shipment just over two months later not only highlights the efficient international registration and supply capabilities of both partners but also brings new treatment options to local patients.

As an important pharmaceutical market in Latin America, Colombia boasts a well-established regulatory system and highly internationalized drug evaluation standards. Kexing Biopharm will use Colombia as a starting point to continuously advance the registration and commercialization of bevacizumab in the Latin American market.

Through this collaboration, leveraging BioDlink's high-standard production and quality systems, as well as Kexing Biopharm's professional expertise in international registrations and market promotion, the two parties will continue to join hands to drive the global layout of more high-quality drugs, providing more accessible treatment solutions for patients worldwide.

About Kexing

Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing Biopharm strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing Biopharm is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.